EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Rigel Pharmaceuticals, Inc.
RIGL

RIGL Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. · NASDAQ
Market Closed
47.24
▼ ⁦-0.08%⁩ (-0.04)
Market Cap$874.0M
Beta1.17
52w Low52w High
24.9552.24
Last Week
⁦-4.41%⁩
Last Month
⁦+20.45%⁩
Last 3 Months
⁦+60.24%⁩
Last Year
⁦+15.95%⁩
EL7 Factor Analysis
How we score this
Overall99
Excellent — top fifth of the marketSuper StockF 6/9SafeBetter than 99% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
83
2.8x▲17.8xTop tier
▸
Growth
70
3.3%▼7.1%Top tier
▸
Quality
100
106.3%▲4.5%Top tier
▸
Safety
85
—2.6xTop tier
▸
Capital Return
83
—2.12%Top tier
▸
Momentum
78
-2.5%▼2.9%Top tier
▸
Sentiment
37
33Bottom tier

Frequently Asked Questions

What is Rigel Pharmaceuticals, Inc. stock?▼

Rigel Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Rigel Pharmaceuticals, Inc.?▼

You can buy Rigel Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Rigel Pharmaceuticals, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Rigel Pharmaceuticals, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Rigel Pharmaceuticals, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Low confidenceCurrent price$47
Analyst target · 2 analysts
$67
⁦+42%⁩
See it clearly undervalued
Range ⁦$49–$85⁩
vs
DCF (estimate)
$55
⁦+17%⁩
Sees it undervalued
⁦9.6⁩% discount · ⁦0⁩% growth
Bottom lineThe two methods broadly agree — estimate range ⁦$55–$67⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 2 analysts setting price target
$67.00
⁦+41.8%⁩
Current Price $47.24·Median $67.00
Low
$49.00
High
$85.00
Current price
$47.24
Average target
$67.00
Street summary

Rigel Pharmaceuticals Price Revision Analysis

Bullish tilt

The stock has seen a radical shift in analyst ratings over the last 30 days, with the average price target jumping from 27.33 to 67, an increase of 145.15%. Despite this significant rise in targets, there is a notable dispersion among analysts (between 49 and 85), indicating a divergence in fair value estimation, although the current price (45.11) is still trading below the lowest announced price target.

As of 2026-08-24
Revisions momentum · 30d
⁦+145.2%⁩
Average rating
★ 3.60
Buy
Analyst coverage
5
Buy conviction
60%
Mixed
Rating activity · 30d
0↑ · 0↓
Target dispersion
76%
Wide
Analyst ratings over time5 analysts rating
3
2
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months3.60 → 3.60
Recent analyst moves
  • = Reiterate2026-08-17
    Piper Sandler
    Neutral
  • = Reiterate2026-08-14
    H.C. Wainwright
    Buy
  • = Reiterate2026-08-06
    Citigroup
    Buy
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    2.80x
    3.94x44.30x
    Very cheap
  • Forward P/E
    12.10x
    4.64x37.16x
    Very cheap
  • EV / EBITDA
    9.61x
    3.77x30.13x
    Very cheap
  • FCF Yield
    9.0%
    -138.2%7.8%
    Exceptional
  • Revenue Growth YoY
    3.3%
    -56.9%93.8%
    Near median
  • EPS Growth YoY
    211.0%
    -160.1%130.2%
    Exceptional
  • Gross Margin
    91.4%
    12.8%90.7%
    Exceptional
  • ROIC
    106.3%
    -155.3%16.0%
    Exceptional
  • Net Debt / EBITDA
    —
    —
  • Dividend Yield
    —
    —
  • Payout Ratio
    —
    —
  • Altman Z-Score
    4.15
    -38.7417.53
    Strong
Financial Analysis
|